Regulatory approval

Published by the Health Canada. Approved

Health Canada approved amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.

This is written in the approval document as:

RYBREVANT (amivantamab for injection) is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic NSCLC with activating EGFR Exon 20 insertion mutations.

Citation

Janssen Inc. Rybrevant (amivantamab-vmjw) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083161.PDF. Revised January 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals